About the company
Who it is, where it is registered and who owns it.
- Description
- UK-headquartered pharmaceutical company
- Founded
- 1978
- Headquarters
- London, United Kingdom
- Industry
- Pharmaceutical industry
- Listed
- London Stock Exchange: HIK
- Legal name
- HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY
- LEI
- 549300BNS685UXH4JI75
- Registered
- United Kingdom, no. 05557934
Who routes its space
The networks announcing its IPv4, by the addresses each announces.
Where its space is
Its IPv4 that IP Geolocation places, by country. A /24 counts for the company using most of it.
- Jordan1,024 · 100.00%
Networks it operates
The autonomous systems registered under its domain, by the IPv4 each announces anywhere.
What the databases see
Addresses each address-keyed database holds in its IPv4, as a share of it, with the largest providers. A /24 counts for the company using most of it; counts overlap.
- 0.27%
- ProxyEmpire0.09%
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- None here
- 0.09%
- None here
- None here
Its address ranges
Its largest IPv4 ranges, then its IPv6 ones, as IP Company draws them, a CIDR a row, with the network announcing each.
| RANGE | IPV4 | ORIGIN |
|---|---|---|
| 185.182.136.0/23 | 512 | AS206553 |
| 185.182.138.0/23 | 512 | AS206553 |
| 193.126.28.96/27 | 32 | AS1897 |
| 213.186.162.16/28 | 16 | AS8376 |
| 213.61.87.0/28 | 16 | AS8220 |
| 12.144.60.32/29 | 8 | AS7018 |
| 12.192.172.88/29 | 8 | AS7018 |
| 12.192.173.112/29 | 8 | AS7018 |
| 12.209.90.176/29 | 8 | AS7018 |
| 12.29.53.120/29 | 8 | AS7018 |
| 41.33.63.36/30 | 4 | AS8452 |
| 2001:1890:1534:2100::/56 | AS7018 | |
| 2001:1890:1534:a100::/56 | AS7018 | |
| 2001:1890:1579:d300::/56 | AS7018 | |
| 2001:1890:1950:a200::/56 | AS7018 | |
| 2001:1890:1e28::/56 | AS7018 |
Names it registers under
The holder names its registry records give, by the IPv4 under each.
- Al-Hikma Pharmaceuticals LLC1,028 · 90.81%
- HIKMA PHARMACEUTICALS40 · 3.53%
- Hikma Farmaceutica Portugal sa32 · 2.83%
- Hikma Pharma GmbH16 · 1.41%
- Hikma Pharmaculicals16 · 1.41%
Test the real build first.
An evaluation license puts a full current build in your hands, with no sampling, so you can measure it against your own traffic before anyone talks about terms.